The Monoclonal Antibody (AGEL1645) specific for Human CD274/PD-L1 is a vital tool for researchers investigating the PD-L1 pathway and its role in cancer immunotherapy. This antibody, known as 29E.2A3, is purified and exhibits high specificity for the CD274 protein, an immune checkpoint molecule that serves as a key regulator of the immune response.PD-L1, also called Programmed Death-Ligand 1, is a crucial immune checkpoint protein that plays a significant role in suppressing the immune system's response to cancer cells. By targeting PD-L1, researchers can gain valuable insights into the mechanisms by which tumors evade immune detection and explore novel therapeutic strategies for enhancing anti-tumor immune responses.
The Monoclonal Antibody 29E.2A3 (AGEL1645) is validated for various applications, including immunohistochemistry and flow cytometry, enabling precise detection and analysis of CD274/PD-L1 expression in different cell types and tissues. Its specificity and reliability make it an indispensable tool for studies focused on cancer biology, immunotherapy, and immune evasion mechanisms, providing critical information for the development of innovative treatments targeting the PD-L1 pathway.
Each lot of this antibody is quality control tested by flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 106 cells in 100 µL volume or 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Swissprot:
Q9NZQ7
Gene ID:
29126
Storage Buffer:
0.2 μm filtered in PBS, pH 7.2. Azide Free (AF)/Low Endotoxin (LE): Contains no stabilizers or stabilizers. Endotoxin level is < 2 EU/mg as Determined by LAL gel clotting assay.
Stability & Storage:
Keep as concentrated solution. Store at 2~8°C and protected from prolonged exposure to light. Do not freeze. Centrifuge before opening to ensure complete recovery of vial contents. This product is guaranteed up to one year from purchase.
Background:
CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.